How to buy Novartis (NVS) shares in Australia
Learn how to easily invest in Novartis shares.
Novartis AG ADR is a drug manufacturers - general business with stocks listed in the US. Novartis shares (NVS) are listed on the NYSE and all prices are listed in US Dollars. Its last market close was US$97.9 – a decrease of 0.24% over the previous week. Here's how to invest if you're based in Australia.
How to buy shares in Novartis
- Compare share trading platforms. To buy shares in a company listed in the US from Australia you'll need to find a trading platform that offers access to US stock markets. Look for a platform with low brokerage and foreign exchange fees.
- Open and fund your brokerage account. Complete an application with your personal and financial details, which will typically include your ID and tax file number. Fund your account with a bank transfer, credit card or debit card.
- Search for Novartis. Find the share by name or ticker symbol: NVS. Research its history to confirm it's a solid investment that matches your financial goals.
- Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until Novartis reaches your desired price. To spread out your risk, look into dollar-cost averaging, which smooths out buying using consistent intervals and amounts.
- Decide on how many to buy. At last close price of US$97.9, weigh your budget against a diversified portfolio that can minimise risk through the market's ups and downs. You may be able to buy a fractional share of Novartis, depending on your broker.
- Check in on your investment. Congratulations, you own a part of Novartis. Optimise your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights.
What's in this guide?
Novartis stock price (NYSE:NVS)Use our graph to track the performance of NVS stocks over time.
Have Novartis's shares ever split?
Novartis's shares were split on a 1116:1000 basis on 9 April 2019. So if you had owned 1000 shares the day before the split, the next day you would own 1116 shares. This wouldn't directly have changed the overall worth of your Novartis shares – just the quantity. However, indirectly, the new 10.4% lower share price could have impacted the market appetite for Novartis shares which in turn could have impacted Novartis's share price.
Novartis shares at a glance
|52-week range||US$79.6389 - US$105.61|
|50-day moving average||US$96.9794|
|200-day moving average||US$96.9679|
|Dividend yield||US$3.461 (3.57%)|
|Earnings per share (TTM)||US$3.86|
Novartis price performance over time
|1 week (2023-11-24)||-0.24%|
|1 month (2023-11-02)||4.06%|
|3 months (2023-09-01)||-2.80%|
|6 months (2023-06-02)||-1.02%|
|1 year (2022-12-02)||8.79%|
|2 years (2021-12-02)||22.45%|
|3 years (2020-12-02)||6.90%|
|5 years (2018-11-30)||20.97%|
Compare trading platforms to buy Novartis shares
Is it a good time to buy Novartis stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. However, this is not a recommendation. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
Is Novartis under- or over-valued?
Valuing Novartis stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Novartis's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Novartis's P/E ratio
Novartis's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 25x. In other words, Novartis shares trade at around 25x recent earnings.
That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.
Novartis's PEG ratio
Novartis's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 5.7688. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Novartis's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
Novartis's EBITDA (earnings before interest, taxes, depreciation and amortisation) is US$21.6 billion (£17 billion).
The EBITDA is a measure of a Novartis's overall financial performance and is widely used to measure a its profitability.
Novartis share price volatility
Over the last 12 months, Novartis's shares have ranged in value from as little as US$79.6389 up to US$105.61. A popular way to gauge a stock's volatility is its "beta".
Beta measures a share's volatility in relation to the market. The market (NYSE average) beta is 1, while Novartis's is 0.51. This would suggest that Novartis's shares are less volatile than average (for this exchange).
|Revenue TTM||US$54.2 billion|
|Operating margin TTM||28.53%|
|Gross profit TTM||US$36.7 billion|
|Return on assets TTM||8.75%|
|Return on equity TTM||16.45%|
|Market capitalisation||US$201.7 billion|
TTM: trailing 12 months
Novartis share dividends
Dividend payout ratio: 50.35% of net profits
Recently Novartis has paid out, on average, around 50.35% of net profits as dividends. That has enabled analysts to estimate a "forward annual dividend yield" of 3.57% of the current stock value. This means that over a year, based on recent payouts (which are sadly no guarantee of future payouts), Novartis shareholders could enjoy a 3.57% return on their shares, in the form of dividend payments. In Novartis's case, that would currently equate to about $3.461 per share.
Novartis's payout ratio would broadly be considered high, and as such this stock could appeal to those looking to generate an income. Bear in mind however that companies should normally also look to re-invest a decent amount of net profits to ensure future growth.
Novartis's most recent dividend payout was on 20 March 2023. The latest dividend was paid out to all shareholders who bought their shares by 9 March 2023 (the "ex-dividend date").
Novartis AG researches, develops, manufactures, and markets healthcare products in Switzerland and internationally. The company offers prescription medicines for patients and physicians. It focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, and oncology, as well as ophthalmology and hematology. Novartis AG has a license and collaboration agreement with Alnylam Pharmaceuticals to develop, manufacture, and commercialize inclisiran, a therapy to reduce LDL cholesterol. Novartis AG was incorporated in 1996 and is headquartered in Basel, Switzerland.
Stocks similar to Novartis
Frequently asked questions
More guides on Finder
How to buy OpenAI stock in Australia
Looking to jump on the AI bandwagon? Here's how you can invest in ChatGPT and its parent company OpenAI from Australia.
Best performing stocks on the ASX in 2023 (Updated weekly)
Looking for the best performing stocks in Australia? We update this list weekly.
Cryptocurrency ETFs explained: A simple guide for investors (2023)
If you’re looking for ways to gain exposure to Bitcoin and other digital currencies, cryptocurrency ETFs could be worth exploring. Find out what crypto ETFs are and how they work in this introductory guide.
How to buy Gol Linhas Aereas Inteligentes SA ADR (GOL) shares in Australia
Steps to owning and managing Gol Linhas Aéreas Inteligentes SA shares from Australia.
How to buy Microsoft (MSFT) shares in Australia
Steps to owning and managing Microsoft shares from in Australia.
A beginner’s guide to Lego investing
Looking for alternative investments? With a ROI of up to 3,593% lego may be worth considering. Read on to find out which lego sets are worth the investment.
The cheapest stock brokers in Australia (Dec 2023)
Find cheap stock brokerage in Australia when buying and selling shares on the ASX and other international exchanges.
What is the money market?
Learn about the money market and everyday consumer money market products.
Is investing in crowdfunding a safe investment?
Equity crowdfunding offers a unique opportunity for investors and for Australian startups, but Australia’s regulatory framework surrounding crowdfunding still lags behind the rest of the world.
The best trading platforms in Australia for 2023
Follow these tips to find the best share trading platform for you.
Ask an Expert